Adverse drug interactions clinically important for the dermatologist.

Adverse drug interactions clinically important for the dermatologist. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Adverse drug interactions clinically important for the dermatologist. Abstract Text:

BACKGROUND: All physicians, including dermatologists, are at risk for prescribing drugs that interact in a harmful way. Although prescribing a harmful drug combination may have serious consequences, no review has examined the drug-drug combinations that are of greatest concern for dermatologists. Our goal is to review the pharmacologic mechanisms of adverse drug interactions, the risky drugs, and the patients who are most vulnerable. In so doing, we hope to provide guidance through a potential minefield of adverse interactions. OBSERVATIONS: Although there are only sparse epidemiologic data regarding the prevalence or cost of adverse drug interactions in dermatology, the consequences may range from a minor loss of therapeutic effect of an administered agent to a life-threatening toxic reaction. We will review methotrexate, cyclosporin A, antifungal agents, antibiotics, retinoids, and antihistamine interactions with each other and with other systemic medications. CONCLUSIONS: An organized reporting system needs to be developed so that statistically meaningful epidemiologic data can be obtained for adverse drug interactions, such as the Medwatch program recently proposed by the Food and Drug Administration. Such a system will provide valuable data regarding drug combinations that may be dangerous and determine the scope of the problem as a public health issue.

Adverse drug interactions clinically important for the dermatologist. Publishing Authors By Initials

For similar investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research

PUBMED ID PMID:

MEDLINE DATE:

Adverse drug interactions clinically important for the dermatologist. Journal Published:

PUBLICATION TYPE: Review

Journal: Archives of dermatology

VOLUME: 131

Page Numbers: 468-73

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Apr

YEAR: 1995

Adverse drug interactions clinically important for the dermatologist. Information

Number of References: 72

LANGUAGE: eng

NlmUniqueID: 372433

Adverse drug interactions clinically important for the dermatologist. Keywords Mesh Terms:

KEYWORDS: Risk Factors

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Adverse drug interactions clinically important for the dermatologist. Information

Substance Name: Cyclosporine

Registry Number: 59865-13-3

Grant and Affiliation Information for Adverse drug interactions clinically important for the dermatologist.

AFFILIATION: Department of Dermatology, Boston University Medical Center, Mass., USA.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Adverse drug interactions clinically important for the dermatologist Related Publications

• A case of portal venous gas after extracorporeal shockwave lithotripsy and obstructive pyelonephritis.
• A hierarchical model for estimating significance levels of non-parametric linkage statistics for large pedigrees.
• Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2.
• Adverse drug interactions clinically important for the dermatologist.
• Antibiotic prophylaxis against bacterial endocarditis in patients undergoing dermatologic surgery.
• Bacterial adherence, colonization, and pathogenicity.
• Cell Shape Dynamics in Escherichia coli.
• Deficiency of PPARbeta/delta in the Epidermis Results in Defective Cutaneous Permeability Barrier Homeostasis and Increased Inflammation.
• Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications.
• Expression of the phospholipid scramblase (PLSCR) gene family during the acute phase response.
• Gene-dropping vs. empirical variance estimation for allele-sharing linkage statistics.
• Glucocorticoid blockade reverses psychological stress-induced abnormalities in epidermal structure and function.
• In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. potential role of hepatocyte nuclear factor-1.
• Medical and vocational cooperation for the aging.
• PPAR and LXR activators regulate ABCA12 expression in human keratinocytes.
• Patterns of expressed emotion and patient coping styles that characterise the families of recent onset schizophrenics.
• Principles of human genetics in relation to insurance medicine and public health.
• Random thoughts continued.
• Regulation of ABCA1 expression in human keratinocytes and murine epidermis.
• Robust Score Statistics for QTL Linkage Analysis.
• Segregation analysis of the Jacobsen data.
• Staphylococcal scalded skin syndrome in an adult.
• Subtyping familial schizophrenia: reliability, concordance, and stability.
• The importance of lipids in cutaneous function.
• The influence of acute infection upon the course of allergy in children; some clinical observations.
• Thematic Review Series: Skin Lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology.
• Thematic review series: Skin Lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis.
• Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells.
• Tumor necrosis factor, cytokines, and the hyperlipidemia of infection.
• Web-Based Identification of Evolutionary Conserved DNA cis-Regulatory Elements.